Concentrations below the detection limit were measured in 19% (n = 13) of OSA group and in 15% (n = 6) of control group for HMW-HA (p = 0.59), and in 28% (n = 19) of patients with OSA and in 58% (n = 23) of control patients for of HYAL-1 (p = 0.002). The gene discussed is HYAL1; the disease is obstructive sleep apnea syndrome.